Clinical Trial Update: A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers [Phase 1]

View source ↗

Summary

A Phase 1 safety study of PF-08046045/SGN-35T sponsored by Seagen has been terminated in adults with advanced lymphomas and Hodgkin disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Cutaneous T-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• PF-08046045/SGN-35T

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Lymphoma, T-Cell, Cutaneous, Hodgkin Disease | Phase 1 | Status: TERMINATED